The purpose of this study is to evaluate the efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan- uveitis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
200
Solution for subcutaneous injection
Solution for subcutaneous injection
Solution for subcutaneous injection
The proportion of responders at Day 56
A response is defined as an improvement of the study eye without deterioration in the contralateral eye.
Time frame: Day 56
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Chandler, Arizona, United States
Unnamed facility
Phoenix, Arizona, United States
Unnamed facility
Beverly Hills, California, United States
Unnamed facility
Los Angeles, California, United States
Unnamed facility
Redlands, California, United States
Unnamed facility
Sacramento, California, United States
Unnamed facility
San Luis Obispo, California, United States
Unnamed facility
Santa Ana, California, United States
Unnamed facility
Victorville, California, United States
Unnamed facility
Golden, Colorado, United States
...and 106 more locations